Turoctocog alfa

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameTuroctocog alfa
Drug Alias NameRecombinant factor VIII (Novo Nordisk)妥罗凝血素α/重组抗血友病因子妥凝血素-8α/重组抗血友病因子Turoctocog alpha/Antihemophilic Factor (Recombinant)Turoctocogalfa +[13] 
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant coagulation factor
Mechanisms of ActionCoagulation factor VIII replacementsCoagulation factor X stimulantsBlood coagulation pathway activation
TargetsCoagulation factor X
Therapy Area/IndicationsHemorrhageHemophilia A
Global Approved IndicationsHemophilia A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2013/10/15
Country/TerritoryFormer Serbia and MontenegroBulgariaUnited States +[32] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesNovo Nordisk A/S
China Registration ClassN/A

Develop Information

Active CompaniesNovo Nordisk A/SNovo Nordisk (China)Pharmaceuticals Co LtdNovo Nordisk Pharmaceuticals
Inactive CompaniesN/A
Active IndicationsHemophilia A
Inactive IndicationsHemorrhage

Other Information

ATC CodeB02BD02
Related LinksWikipediaDrugBankKEGG